|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Hypertension | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Diabetes Mellitus | |||||
| Diabetes Mellitus, Type 2 | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Endocrine System Diseases | |||||
| Glucose Metabolism Disorders | |||||
| Metabolic Diseases | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| carvedilol | |||||
| metoprolol | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Metoprolol succinate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic alpha-Antagonists | |||||
| Adrenergic Antagonists | |||||
| Adrenergic beta-Antagonists | |||||
| Anti-Arrhythmia Agents | |||||
| Antihypertensive Agents | |||||
| Autonomic Agents | |||||
| Cardiovascular Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sympatholytics | |||||
| Therapeutic Uses | |||||
| Vasodilator Agents | |||||
| 7 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||